Effects of peginterferon beta-1a injection: A Synthesis of Findings from 20 Studies

  1. Home
  2. Effects of peginterferon beta-1a injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of peginterferon beta-1a injection: A Synthesis of Findings from 20 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of peginterferon beta-1a injection: A Synthesis of Findings from 20 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Peginterferon beta-1a is a promising new treatment for relapsing-remitting multiple sclerosis (RRMS) that has shown potential to reduce injection frequency while maintaining efficacy compared to existing interferon beta formulations. 5 , 8 , 17 , 13 , 20 . Peginterferon beta-1a has a longer half-life and higher blood concentration compared to conventional interferon beta formulations. 2 , 18 . Therefore, it has the potential to be effective with a dosing schedule of once every two weeks, similar to the effects of conventional interferon beta formulations that require weekly or multiple doses. 8 , 13 . Peginterferon beta-1a significantly reduced the frequency of relapses, disability progression, and new lesion development. 8 . Furthermore, patients reported high levels of satisfaction and ease of use with peginterferon beta-1a, leading to improved adherence to treatment. 5 , 20 , 3 .

Benefits and Risks

Benefit Summary

Peginterferon beta-1a is a promising new treatment for RRMS that has shown potential to reduce injection frequency while maintaining efficacy compared to existing interferon beta formulations. Additionally, patients reported high levels of satisfaction and ease of use with peginterferon beta-1a, leading to improved adherence to treatment.

Risk Summary

Peginterferon beta-1a can cause side effects such as flu-like symptoms and injection-site reactions, similar to conventional interferon beta formulations. 2 , 8 , 7 , 16 , 3 . In rare cases, side effects such as skin discoloration and hypersensitivity have also been reported. 6 .

Comparison Between Studies

Commonalities Among Studies

Multiple studies suggest that peginterferon beta-1a has the potential to reduce injection frequency while maintaining efficacy compared to conventional interferon beta formulations in treating RRMS.

Differences Between Studies

There are slight variations in the results regarding the effectiveness and safety of peginterferon beta-1a across different studies. These variations may be attributed to differences in study designs and patient populations. For instance, 8 suggests that peginterferon beta-1a exhibits similar efficacy to conventional interferon beta formulations, while 9 indicates that there may be racial differences in pharmacokinetics.

Consistency and Discrepancies in Results

Multiple studies consistently point to peginterferon beta-1a as a promising new treatment for RRMS that has the potential to reduce injection frequency while maintaining efficacy compared to existing interferon beta formulations. However, there are variations in the reported frequency and severity of side effects, warranting further research.

Considerations for Real-Life Application

Peginterferon beta-1a can be an effective treatment option for RRMS, but it is crucial to consider the potential risks of side effects and use it under the guidance of a physician. Additionally, patients have reported high satisfaction and ease of use with peginterferon beta-1a, leading to improved adherence to treatment. However, it is important to note that not all patients will experience positive outcomes. It is essential to consult with a physician to select the appropriate treatment plan.

Limitations of Current Research

Research on peginterferon beta-1a is still in its early stages, and there is a lack of data on long-term safety and efficacy. Additionally, variations in study designs and patient populations may influence the results.

Future Research Directions

Large-scale clinical trials are needed to assess the long-term safety and efficacy of peginterferon beta-1a. Furthermore, research is required to investigate the influence of factors such as race and age on the effectiveness and side effects of peginterferon beta-1a.

Conclusion

Peginterferon beta-1a is a promising new treatment for RRMS that has shown potential to reduce injection frequency while maintaining efficacy compared to existing interferon beta formulations. However, it is crucial to consider the potential risks of side effects and use it under the guidance of a physician. Future research holds promise for providing further insights into the safety and efficacy of peginterferon beta-1a.

Literature analysis of 20 papers
Positive Content
18
Neutral Content
1
Negative Content
1
Article Type
6
1
1
6
20
1.

Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers.

Author: SiéP, AlbaredeJ L, RobertM, BoulouxC, LansenJ, ChigotC, CorrellS, ThouvenotJ P, BoneuB

Good tolerance
Liver enzyme elevation
Platelet reduction

Pentosan polysulfate (PPS) is a drug that can be used to treat certain medical conditions. This study investigated the tolerance and pharmacological activity of PPS in 30 healthy volunteers. PPS was well tolerated, with the most common side effects being increased transaminase levels and decreased platelet counts. The study found that PPS significantly prolonged the activated partial thromboplastin time (APTT) and induced a weak but significant circulating anti-Xa activity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.

Author: HuXiao, MillerLarisa, RichmanSandra, HitchmanStacy, GlickGabrielle, LiuShifang, ZhuYing, CrossmanMary, NestorovIvan, GronkeRobert S, BakerDarren P, RoggeMark, SubramanyamMeena, DavarGudarz

Treat relapsing MS
Flu-like symptoms
Neutropenia

This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a) in healthy volunteers. PEG-IFN beta-1a showed greater exposure, longer half-life, and lower clearance than unmodified IFN beta-1a. It was well tolerated with only transient reductions in neutrophils and lymphocytes.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

PEGylated IFNβ-1a in the treatment of multiple sclerosis.

Author: KhanUmair Tahir, TanasescuRadu, ConstantinescuCris S

MS treatment
Poor adherence
Side effects

Injectable therapies for relapsing-remitting multiple sclerosis (RRMS) are effective but may suffer from poor adherence due to frequent injections and side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.

Author: SeddighzadehAli, HungSerena, SelmajKrzysztof, CuiYue, LiuShifang, SperlingBjoern, CalabresiPeter A

MS treatment
Patient satisfaction
Safety evaluation

This sub-study evaluated the safety, tolerability, ease-of-use, and patient satisfaction with a single-use autoinjector administering subcutaneous peginterferon-β1a in relapsing-remitting multiple sclerosis (MS) patients. The results indicate that the autoinjector was safe, well-tolerated, and easy to use, with high patient satisfaction. This suggests that a single-use autoinjector could be a convenient and acceptable option for administering peginterferon-β1a to MS patients.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection.

Author: CogheGiancarlo, AtzoriLaura, FrauJessica, FenuGiuseppe, LoreficeLorena, MarrosuMaria Giovanna, CoccoEleonora

Skin lesions

This case report describes a 42-year-old woman who developed skin lesions after receiving subcutaneous interferon beta-1a. The lesions, characterized by hypochromic macules and hyperpigmentation, suggest a possible localized pigmentation disorder associated with interferon beta treatment.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study.

Author: ZhaoYuan, MokliatchoukOksana, RamiaNancy F, NaylorMaria L, ButtsCherié L

MS treatment

Black/African American participants are underrepresented in clinical trials for multiple sclerosis, despite experiencing a greater burden of disease. This study indicates bioequivalence of subcutaneous and intramuscular injection of peginterferon β-1a in Black and White participants, enabling future research to assess differences in drug response and side effects.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.

Author: HendinBarry A

Treats relapsing multiple sclerosis
Flu-like symptoms
Injection site reactions

This study presents three cases of patients who either initiated therapy with peginterferon beta-1a or switched from another interferon for the treatment of relapsing multiple sclerosis. All three cases had positive outcomes. Peginterferon beta-1a, administered subcutaneously every two weeks, may be a beneficial alternative for patients who prefer less frequent injections.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

Author: EnglishClayton, AloiJoseph J

Treatment of MS

This review critically evaluates the safety profile and efficacy data of disease-modifying agents for multiple sclerosis (MS) approved by the US Food and Drug Administration (FDA) from 2010 to the present. The review also provides cost and available pharmacoeconomic data about each new treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.

Author: HuXiao, ShangShulian, NestorovIvan, HasanJawad, SeddighzadehAli, DawsonKatherine, SperlingBjørn, WerneburgBrian

Multiple sclerosis treatment

This study investigates the pharmacokinetic activity, safety, and tolerability of subcutaneous peginterferon beta-1a and interferon beta-1a in healthy subjects. The study aimed to compare the two treatments, which have shown efficacy in relapsing-remitting multiple sclerosis, but lacked direct comparisons.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

13.

Peginterferon beta-1a (Plegridy) for multiple sclerosis.

Author:

Similar adverse effects
Similar efficacy

Pegylated interferon beta-1a (Plegridy), a subcutaneous injection given every 2 weeks, appears to be similar in efficacy and adverse effects to older interferon formulations that must be injected more frequently.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.

Author: KieseierBernd C, ArnoldDouglas L, BalcerLaura J, BoykoAlexey A, PelletierJean, LiuShifang, ZhuYing, SeddighzadehAli, HungSerena, DeykinAaron, SheikhSarah I, CalabresiPeter A

Improved efficacy
Reduced relapse rate
Well tolerated

Peginterferon beta-1a efficacy was maintained beyond 1 year, with greater effects observed with every 2 week versus every 4 week dosing.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Pegylated interferons: a nurses' review of a novel multiple sclerosis therapy.

Author: HowleyAnne, KremenchutzkyMarcelo

MS compliance
Pegylated interferon beta-1a

Pegylation is a method used to modify drugs to extend their bioavailability. This review discusses the potential of peginterferon beta-1a, a pegylated form of interferon beta-1a, to improve compliance and clinical outcomes in patients with multiple sclerosis (MS).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study.

Author: HendinBarry, HuangDeRen, WraySibyl, NaismithRobert T, RosenblattSheri, ZambranoJavier, WerneburgBrian

Multiple sclerosis treatment
Peginterferon β-1a efficacy
Injection-site reaction

This Delphi analysis aimed to determine consensus on injection-site reactions (ISRs) and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

18.

In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.

Author: HuXiao, OlivierKenneth, PolackEvelyne, CrossmanMary, ZokowskiKatie, GronkeRobert S, ParkerSuezanne, LiZhaoyang, NestorovIvan, BakerDarren P, ClarkeJanet, SubramanyamMeena

MS treatment
Neutralizing antibodies

This study investigated the pharmacokinetic (PK) and pharmacodynamic (PD) parameters, immunogenicity, and safety of PEG-IFN β-1a in Rhesus monkeys. PEG-IFN β-1a showed greater exposure, longer half-life, and lower clearance than unmodified IFN β-1a. It induced neutralizing antibodies after 5 weeks of treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

Author: TramacereIrene, VirgiliGianni, PerducaVittorio, LucenteforteErsilia, BenedettiMaria Donata, CapobussiMatteo, CastelliniGreta, FrauSerena, Gonzalez-LorenzoMarien, FeatherstoneRobin, FilippiniGraziella

Decreased disease activity
MS treatment
Safety uncertainty
Significant disability

Multiple sclerosis (MS) is a disease affecting the brain and spinal cord, primarily affecting young adults, with women being affected more often than men. While treatments for MS can slow the disease's progression, there's still uncertainty about their safety.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.

Author: HendinBarry, NaismithRobert T, WraySibyl E, HuangDeren, DongQunming, LivingstonTerrie, JonesDaniel L, WatsonCrystal, JhaveriMehul

Improved convenience
Improved treatment satisfaction
Not applicable

Switching patients with relapsing multiple sclerosis from other interferon (IFN) therapies to subcutaneous (SC) peginterferon beta-1a significantly improved treatment satisfaction, particularly in terms of convenience.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.